openPR Logo
Press release

T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report

07-11-2017 12:24 PM CET | Health & Medicine

Press release from: Kuick Resarch

T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. T-Cell Lymphoma Market Analysis

2. Mechanism of T-Cell Lymphoma Therapeutics

3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview

4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. T-Cell Lymphoma Drug Market Future Prospects

6. T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III

7. Marketed T-Cell Lymphoma Drug Clinical Insight
7.1 Belinostat (Beleodaq)
7.2 Denileukin Diftitox (ONTAK)
7.3 Mogamulizumab (Poteligeo)
7.4 Brentuximab Vedotin (Adcetris)
7.5 Pralatrexate (Difolta/Folotyn)
7.6 Interferon gamma 1a Biosimilar (Imunomax-γ)
7.7 Nelarabine (Arranon/ Atriance)
7.8 Vorinostat (Zolinza)
7.9 Romidepsin (Istodax)
7.10 Bexarotene Topical (Targretin Gel)
7.11 Bexarotene Oral (Targretin Oral)
7.12 Chlormethine (Ledaga/Valchlor
7.13 Methoxsalen Solution (UVADEX)
7.14 Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)
7.15 Interferon alpha-2a (Roferon-A)

8. Discontinued & No Development Reported in T-Cell Lymphoma Drug in Clinical Pipeline
8.1 Discontinued
8.2 No Development Reported

9. Competitive Landscape
9.1 Actelion Pharmaceuticals
9.2 Allos Therapeutics
9.3 Astellas Pharma
9.4 BioCryst Pharmaceuticals
9.5 Bristol-Myers Squibb
9.6 Chipscreen Biosciences
9.7 Celgene Corporation
9.8 Eisai
9.9 Genmab
9.10 Galderma
9.11 Inovio Pharmaceuticals
9.12 Johnson & Johnson Pharmaceutical Research & Development
9.13 Karyopharm Therapeutics
9.14 Kyowa Hakko Kirin
9.15 Nippon Kayaku
9.16 Novartis
9.17 Neumedicines
9.18 Onyx Pharmaceuticals
9.19 Roche
9.20 Seattle Genetics
9.21 Shionogi
9.22 Soligenix
9.23 TetraLogic Pharmaceuticals
9.24 ZIOPHARM Oncology

Download Report: https://www.kuickresearch.com/report-Global-T-Cell-Lymphoma-Market-&-Clinical-Pipeline-Insight.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report here

News-ID: 619066 • Views: 259

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Lymphoma

Lymphoma Drugs Market Growth 2019-2024
According to 24 Market Reports study, over the next five years the Lymphoma Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the
Lymphoblastic Lymphoma Market : Overview and Analysis
Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other
Burkitt Lymphoma Therapeutics Market Key Growth Drivers
Burkitt lymphoma is a form of non-Hodgkin's lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated. Endemic NHL is also known as African type and affects African children aged between
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
Lymphoma Therapeutics Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Lymphoma Therapeutics Market Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-lymphoma-therapeutics-market-report-2017-1541149 In this report, the United States Lymphoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of